Four signal stages for the intersection. by Bin Zhao (276445)

“…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”

Dynamic system state in demand scenarios 3. by Bin Zhao (276445)

“…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”

Dynamic system state in demand scenarios 1. by Bin Zhao (276445)

“…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”

Characteristics comparison of related literature. by Bin Zhao (276445)

“…Numerical experiments using actual survey data from Kunshan City yield several noteworthy findings: (1) An optimal moderate-sized time step exists for rolling optimization to minimize either the average delay time or total costs; specifically, an excessively small time step may increase vehicle average delay time or total costs; (2) The percentage of delay reduction achieved by our method, compared to Synchro software, reaches a maximum of approximately 70% when traffic demand is moderate and the initial state is low; and (3) The percentage reduction in average delay or total costs compared to Synchro initially increases and then decreases with rising traffic intensity.…”

Workflow of the study. by Hongliang Chen (538815)

“…Enrichment and immune infiltration analyses revealed significant differences in mitochondrial structure and function, immune cell disorders, and signaling pathway activation between the high- and low-mitochondrial gene expression UC groups. …”

Phage–host adsorption results. by Rokaiya Nurani Shatadru (22656316)

Improving QoL through the use of STAT-ON™. by Daniel Rodriguez-Martin (22411006)

“…<div><p>Parkinson’s Disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide, with significant economic and social implications. The increasing prevalence of PD, coupled with rising healthcare costs, necessitates cost-effective solutions for patient management. …”

Scenario 1. Moderate patient with STAT-ON™. by Daniel Rodriguez-Martin (22411006)

“…<div><p>Parkinson’s Disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide, with significant economic and social implications. The increasing prevalence of PD, coupled with rising healthcare costs, necessitates cost-effective solutions for patient management. …”

Scenario 2. Advanced patient with STAT-ON™. by Daniel Rodriguez-Martin (22411006)

“…<div><p>Parkinson’s Disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide, with significant economic and social implications. The increasing prevalence of PD, coupled with rising healthcare costs, necessitates cost-effective solutions for patient management. …”

Included studies basic characteristics. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

All data extracted. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for TNF- by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Comparisons of separability and variance of evidence distributions when noise and variability are manipulated independently for the 4-layer CNN across the three experiments. by Medha Shekhar (19502698)

“…On the other hand, separability of evidence distributions decreased significantly from the low to high variability condition and the variance of evidence distribution increased from the low to high variability conditions for all experiments.…”

Serum phosphorus level. by Naoki Suzuki (308620)

“…Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p < 0.01). …”

Characteristics of the study participants. by Naoki Suzuki (308620)

“…Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p < 0.01). …”

Serum albumin level. by Naoki Suzuki (308620)

“…Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p < 0.01). …”

Serum calcium levels corrected for albumin. by Naoki Suzuki (308620)

“…Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p < 0.01). …”

The proportion of the dosage of tenapanor. by Naoki Suzuki (308620)

“…Laxative use decreased significantly in the tenapanor group, from 58.2% at baseline to 35.6% at week 23 (p < 0.01). …”

Bias risk assessment of included studies. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”